Jessica P Hwang1, Bruno P Granwehr2, Harrys A Torres2, Maria E Suarez-Almazor2, Thomas P Giordano2, Andrea G Barbo2, Heather Y Lin2, Michael J Fisch2, Elizabeth Y Chiao2. 1. The University of Texas MD Anderson Cancer Center; Houston Veterans Affairs (VA) Health Sciences Research and Development, Michael E. DeBakey VA Medical Center; and Baylor College of Medicine, Houston, TX jphwang@mdanderson.org. 2. The University of Texas MD Anderson Cancer Center; Houston Veterans Affairs (VA) Health Sciences Research and Development, Michael E. DeBakey VA Medical Center; and Baylor College of Medicine, Houston, TX.
Abstract
PURPOSE: To determine the rates of HIV testing and infection among patients with cancer at initiation of systemic cancer therapy. METHODS: We conducted a retrospective cohort study of adults with cancer who registered at a comprehensive cancer center from January 2004 through April 2011 and received systemic cancer therapy. We determined rates of HIV-1/2 and/or Western blot testing and HIV positivity at initiation of systemic cancer therapy. Multivariable logistic regression was used to determine predictors of HIV testing. RESULTS: Of 18,874 patients with cancer who received systemic cancer therapy during the study period, 3,514 (18.6%) were tested for HIV at initiation of cancer therapy. The prevalence of positive HIV test results was 1.2% (41 of 3,514), and the prevalence of newly diagnosed HIV was 0.3% (12 of 3,514). The HIV testing rate was lower in black than in white patients (13.7% v 19.2%), but the prevalence of positive test results was higher in black patients (4.5%) than in any other racial/ethnic group. Among patients with AIDS-defining cancers (eg, non-Hodgkin lymphoma and cervical cancer), predictors of HIV testing were history of non-Hodgkin lymphoma, younger age, and registration after 2006. Among patients with non-AIDS-defining cancers, predictors of HIV testing were younger age, registration after 2006, male sex, history of illicit drug use or sexually transmitted disease, having a hematologic malignancy, and black race. CONCLUSION: The prevalence of HIV infection among patients with cancer was 1.2%, higher than the 0.1% prevalence threshold above which national guidelines recommend routine opt-out testing; however, the overall HIV testing rate was low.
PURPOSE: To determine the rates of HIV testing and infection among patients with cancer at initiation of systemic cancer therapy. METHODS: We conducted a retrospective cohort study of adults with cancer who registered at a comprehensive cancer center from January 2004 through April 2011 and received systemic cancer therapy. We determined rates of HIV-1/2 and/or Western blot testing and HIV positivity at initiation of systemic cancer therapy. Multivariable logistic regression was used to determine predictors of HIV testing. RESULTS: Of 18,874 patients with cancer who received systemic cancer therapy during the study period, 3,514 (18.6%) were tested for HIV at initiation of cancer therapy. The prevalence of positive HIV test results was 1.2% (41 of 3,514), and the prevalence of newly diagnosed HIV was 0.3% (12 of 3,514). The HIV testing rate was lower in black than in white patients (13.7% v 19.2%), but the prevalence of positive test results was higher in black patients (4.5%) than in any other racial/ethnic group. Among patients with AIDS-defining cancers (eg, non-Hodgkin lymphoma and cervical cancer), predictors of HIV testing were history of non-Hodgkin lymphoma, younger age, and registration after 2006. Among patients with non-AIDS-defining cancers, predictors of HIV testing were younger age, registration after 2006, male sex, history of illicit drug use or sexually transmitted disease, having a hematologic malignancy, and black race. CONCLUSION: The prevalence of HIV infection among patients with cancer was 1.2%, higher than the 0.1% prevalence threshold above which national guidelines recommend routine opt-out testing; however, the overall HIV testing rate was low.
Authors: Ryan C Burke; Kent A Sepkowitz; Kyle T Bernstein; Adam M Karpati; Julie E Myers; Benjamin W Tsoi; Elizabeth M Begier Journal: AIDS Date: 2007-07-31 Impact factor: 4.177
Authors: Juan Berenguer; Pilar Miralles; José María Ribera; Rafael Rubio; Eulalia Valencia; Beatriz Mahillo; Vicente Pintado; Rosario Palacios; María Luisa Montes; María Jesús Téllez; José La Cruz; Julián Torre-Cisneros; Francisco Rodríguez-Arrondo; María Antonia Sepúlveda; Félix Gutiérrez; Galo Peralta; Vicente Boix Journal: J Acquir Immune Defic Syndr Date: 2008-04-01 Impact factor: 3.731
Authors: H Tilly; U Vitolo; J Walewski; M Gomes da Silva; O Shpilberg; M André; M Pfreundschuh; M Dreyling Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: M Alfa-Wali; T Allen-Mersh; A Antoniou; D Tait; T Newsom-Davis; B Gazzard; M Nelson; M Bower Journal: Ann Oncol Date: 2011-03-28 Impact factor: 32.976
Authors: Elizabeth Y Chiao; Bruce J Dezube; Susan E Krown; William Wachsman; Malcolm V Brock; Thomas P Giordano; Ronald Mitsuyasu; Liron Pantanowitz Journal: JAMA Date: 2010-07-21 Impact factor: 56.272
Authors: John G Bartlett; Bernard M Branson; Kevin Fenton; Benjamin C Hauschild; Veronica Miller; Kenneth H Mayer Journal: JAMA Date: 2008-08-27 Impact factor: 56.272
Authors: Gemma Reynolds; Gabrielle Haeusler; Monica A Slavin; Benjamin Teh; Karin Thursky Journal: Support Care Cancer Date: 2021-03-24 Impact factor: 3.603
Authors: S J Bogers; S H Hulstein; M F Schim van der Loeff; G J de Bree; P Reiss; J E A M van Bergen; S E Geerlings Journal: EClinicalMedicine Date: 2021-05-08